EPO and chronic kidney disease: Inhibition of iFGF23 signaling with rh-cFGF23 in CKD mice resulted in decreased erythroid cell apoptosis, upregulation of renal and BM HIF1α and subsequent EPO mRNA expression, elevated serum EPO levels and amelioration of iron deficiency.